Brief: Enveric Biosciences Selects EB-003 As Lead Drug Candidate From EVM301 Series
28/12/2023 13:37
Dec 28 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES SELECTS EB-003 AS LEAD DRUG CANDIDATE
FROM
EVM301 SERIES
* ENVERIC BIOSCIENCES INC - TO INITIATE PRECLINICAL
DEVELOPMENT OF
EB-003 IN 2024 IN PREPARATION FOR IND SUBMISSION
Source text for Eikon: ID:nBw99MY2pa
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003